Opening book details…
About this nonfiction
Comparison of platinum combination chemotherapy plus pembrolizumab versus platinum combination chemotherapy plus nivolumab–ipilimumab for treatment-naive advanced non-small-cell lung cancer in Japan (JCOG2007): an open-label, multicentre, randomised, phase 3 trial by Shiraishi, Yoshimasa (author);Nomura, Shogo (author);Sugawara, Shunichi (author);Horinouchi, Hidehito (author);Yoneshima, Yasuto (author);Hayashi, Hidetoshi (author);Azuma, Koichi (author);Hara, Satoshi (author);Niho, Seiji (author);Morita, Ryo (author);Yamaguchi, Masafumi (author);Yokoyama, Toshihide (author);Yoh, Kiyotaka (author);Kurata, Takayasu (author);Okamoto, Hiroaki (author);Okamoto, Masaki (author);Kijima, Takashi (author);Kasahara, Kazuo (author);Fujiwara, Yutaka (author);Murakami, Shuji (author);Kanda, Shintaro (author);Akamatsu, Hiroaki (author);Takemoto, Shinnosuke (author);Kaneda, Hiroyasu (author);Kozuki, Toshiyuki (author);Ando, Masahiko (author);Sekino, Yuta (author);Fukuda, Haruhiko (author);Ohe, Yuichiro (author);Okamoto, Isamu (author) is a nonfiction available to read on EtoBox.
It is typically read by self-directed learners exploring a subject in depth.
Common subject areas: history, science, philosophy, social sciences.
- Author
- Shiraishi, Yoshimasa (author);Nomura, Shogo (author);Sugawara, Shunichi (author);Horinouchi, Hidehito (author);Yoneshima, Yasuto (author);Hayashi, Hidetoshi (author);Azuma, Koichi (author);Hara, Satoshi (author);Niho, Seiji (author);Morita, Ryo (author);Yamaguchi, Masafumi (author);Yokoyama, Toshihide (author);Yoh, Kiyotaka (author);Kurata, Takayasu (author);Okamoto, Hiroaki (author);Okamoto, Masaki (author);Kijima, Takashi (author);Kasahara, Kazuo (author);Fujiwara, Yutaka (author);Murakami, Shuji (author);Kanda, Shintaro (author);Akamatsu, Hiroaki (author);Takemoto, Shinnosuke (author);Kaneda, Hiroyasu (author);Kozuki, Toshiyuki (author);Ando, Masahiko (author);Sekino, Yuta (author);Fukuda, Haruhiko (author);Ohe, Yuichiro (author);Okamoto, Isamu (author)
- Publisher
- Elsevier BV
- Published
- 2024
- Language
- EN
- Category
- nonfiction
More by Shiraishi, Yoshimasa (author);Nomura, Shogo (author);Sugawara, Shunichi (author);Horinouchi, Hidehito (author);Yoneshima, Yasuto (author);Hayashi, Hidetoshi (author);Azuma, Koichi (author);Hara, Satoshi (author);Niho, Seiji (author);Morita, Ryo (author);Yamaguchi, Masafumi (author);Yokoyama, Toshihide (author);Yoh, Kiyotaka (author);Kurata, Takayasu (author);Okamoto, Hiroaki (author);Okamoto, Masaki (author);Kijima, Takashi (author);Kasahara, Kazuo (author);Fujiwara, Yutaka (author);Murakami, Shuji (author);Kanda, Shintaro (author);Akamatsu, Hiroaki (author);Takemoto, Shinnosuke (author);Kaneda, Hiroyasu (author);Kozuki, Toshiyuki (author);Ando, Masahiko (author);Sekino, Yuta (author);Fukuda, Haruhiko (author);Ohe, Yuichiro (author);Okamoto, Isamu (author)
Similar books
- Nivolumab Plus Ipilimumab Combination Therapy in Cancer: Current Evidence to Date — Nikoo, Marzieh; Rabiee, Fatemeh; Mohebbi, Hossein; Eghbalifard, Negar; Rajabi, Hamid; Yazdani, Yalda; Sakhaei, Delaram; Khosravifarsani, Mohammadreza; Akhavan-Sigari, Reza (2023)
- Nivolumab Plus Ipilimumab in Hepatocellular Carcinoma — Mathew Vithayathil & Rohini Sharma (2025)
- Nivolumab Plus Ipilimumab Versus Nivolumab in Microsatellite Instability-high Metastatic Colorectal Cancer (CheckMate 8HW): a Randomised, Open-label, Phase 3 Trial — Prof Thierry André MD & Elena Elez MD & Heinz-Josef Lenz MD & Lars Henrik Jensen MD & Prof Yann Touchefeu MD & Eric Van Cutsem MD & Rocio Garcia-Carbonero MD & David Tougeron MD & Guillermo Ariel Mendez MD & Michael Schenker MD & Christelle de la... (2025)
- Neoadjuvant Chemotherapy Plus Nivolumab with or Without Ipilimumab in Operable Non-small Cell Lung Cancer: the Phase 2 Platform NEOSTAR Trial — Tina Cascone & Cheuk H. Leung & Annikka Weissferdt & Apar Pataer & Brett W. Carter & Myrna C. B. Godoy & Hope Feldman & William N. William & Yuanxin Xi & Sreyashi Basu & Jing Sun & Shalini S. Yadav & Frank R. Rojas Alvarez & Younghee Lee & Aditya... (2023)
- Nivolumab Plus Ipilimumab Versus Lenvatinib or Sorafenib as First-line Treatment for Unresectable Hepatocellular Carcinoma (CheckMate 9DW): an Open-label, Randomised, Phase 3 Trial — Thomas Yau MD & Prof Peter R Galle MD & Thomas Decaens MD & Prof Bruno Sangro MD & Shukui Qin MD & Leonardo G da Fonseca MD & Hatim Karachiwala MD & Prof Jean-Frederic Blanc MD & Prof Joong-Won Park MD & Prof Edward Gane MD & Matthias Pinter MD & Ana... (2025)
- Niraparib Plus Nivolumab or Niraparib Plus Ipilimumab in Patients with Platinum-sensitive Advanced Pancreatic Cancer: a Randomised, Phase 1B/2 Trial — Reiss, Kim A; Mick, Rosemarie; Teitelbaum, Ursina; O'Hara, Mark; Schneider, Charles; Massa, Ryan; Karasic, Thomas; Tondon, Rashmi; Onyiah, Chioma; Gosselin, Mary Kate; Donze, Alyssa; Domchek, Susan M; Vonderheide, Robert H (2022)